Introduction: Atrial fibrillation (AF) is a prevalent cardiovascular disease among patients with diabetes mellitus (DM) . Heart failure risk (HF) & In-hospital outcomes surrounding AF are poorly understood among diabetes

Methods: We queried the National Inpatient Sample from 2016 to 2018 for patients with DM as a principal diagnosis with & without underlying AF as a secondary diagnosis. The primary outcome was mortality, while secondary outcomes were cardiogenic shock (CS) , Cardiac Arrest (CA) , Mean Length of stay (LOS) , Total hospital cost (THC) , & average patient charge (APC) . Multivariable regression models were applied for outcomes

Results: A total of 1,211,870 patients with DM were admitted with 11.9% having AF. AF vs. No AF cohorts were mean age of 71.4 years vs. 59.3 years & Females (35.5% vs. 41.7%) . CAD, HF & CKD were more prevalent (51.6% vs. 25.9%) , (47.8% vs. 16.2%) , (52.5% vs. 34.6%) in DM with AF. Higher inpatient mortality, CS, CA, APC & LOS were observed in the AF group (Table 1)

Conclusion: One in nine patients hospitalized with DM has AF. Comorbid heart & kidney disease were prevalent in DM patients with AF. Higher in-hospital mortality & adverse cardiovascular outcomes were observed in these patients, with greater costs for the hospital & patient. Preventative treatment addressing HF risk in DM patients with AF maybe improve outcomes & costs.

Disclosure

M.Fatuyi: n/a. L.Pereira: None. V.Sharma: None. L.Khokhlov: None. V.Namdarizandi: None. A.Zain elabidin: None. R.T.Orji: None. K.Shemisa: Speaker's Bureau; AstraZeneca, Bayer AG, Boehringer Ingelheim International GmbH, ESPERION Therapeutics, Inc., Merck & Co., Inc., Pfizer Inc.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.